M. Reinhardt et al., IMPROVED DOSE CONCEPT FOR RADIOIODINE THERAPY OF MULTIFOCAL AND DISSEMINATED FUNCTIONAL THYROID AUTONOMY, European journal of endocrinology, 132(5), 1995, pp. 550-556
The present study analyzes the improvement of the outcome of radioiodi
ne therapy in nonimmunogenic hyperthyroidism by adapting the target do
se to the Tc-99m-pertechnetate thyroid uptake under suppression (TcTUs
) prior to radioiodine therapy. The TcTUs is a substitute for the non-
suppressible iodine turnover. The 89 patients presented with a basal t
hyrotropin level of <0.1 mU/1, normal values far Gee triiodothyronine
and thyroxine and with multifocal or disseminated thyroid autonomy. Th
ese terms describe the scintigraphic distribution pattern of autonomou
s iodine turnover. Thirty-two patients had a TcTUs between 1.6 and 3.2
% (group A) and 57 had a TcTUs > 3.2% (group B). Fifty-Eve patients (t
hree of group A and 52 of group B) were treated previously for overt h
yperthyroidism with antithyroid drugs. Target doses of 150 and 200 Gy
were used in both groups and 300 Gy in group B only. Six months after
radioiodine therapy, a basal TSH level of greater than or equal to 0.5
mU/I as criterion of therapy success was observed in 94% of group A a
nd in 54% of group B. Further differentiation of group B shows an incr
easing success rate with the target dose used: 45% after 150 Gy, 50% a
fter 200 Gy and 90% after 300 Gy. In patients with a basal TSH level o
f <0.5 mU/1 after radioiodine therapy, the TcTUs was evaluated again.
Persistence of functional thyroid autonomy, defined as TcTUs > 1.6%, w
as found in 89% (one patient of group A, 24 patients of group B) and s
till observed a high extent of autonomous function in 25% of them, evi
denced by a TcTUs > 3.2% (seven patients of group B, target doses of 1
50 or 200 Gy). No case of overt hypothyroidism was observed within the
first 6 months after radioiodine therapy and no difference was found
in therapy outcome between multifocal and disseminated thyroid autonom
y. As a consequence, the target dose should be adapted to the TcTUs pr
ior to radioiodine therapy in the range of 150-300 Gy to the total thy
roid gland.